Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
48 hedge funds and large institutions have $97.1M invested in Cidara Therapeutics in 2015 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 20 increasing their positions, 10 reducing their positions, and 4 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 10
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
16% more capital invested
Capital invested by funds: $83.7M → $97.1M (+$13.4M)
4% more funds holding
Funds holding: 46 → 48 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Aisling Capital
New York
|
+$14.6M |
| 2 |
PA
Perceptive Advisors
New York
|
+$6.33M |
| 3 |
AIC
AWM Investment Company
New York
|
+$1.18M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$754K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$672K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$1.01M |
| 2 |
Millennium Management
New York
|
-$828K |
| 3 |
TCIM
TIAA CREF Investment Management
New York
|
-$179K |
| 4 |
Norges Bank
Oslo,
Norway
|
-$140K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$112K |
CDTX Hedge Fund Activity: Q3 2015 in Review
48 of the 3,589 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q3 2015, worth a combined $97.1M — up 16% from $83.7M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CDTX positions and 4 closed out — a net gain of 2 holders — while 20 added to existing stakes and 10 trimmed.
The largest buyer was Aisling Capital, opening a new position worth an estimated $14.6M. The largest seller was Acuta Capital Partners, cutting an estimated $1.01M.
- 48 institutional investors held Cidara Therapeutics (CDTX) as of Q3 2015, up from 46 in Q2 2015.
- Funds reported $97.1M of Cidara Therapeutics stock for Q3 2015, up 16% quarter-over-quarter.
- 6 funds opened new Cidara Therapeutics positions in Q3 2015 and 4 closed out, a net change of +2 holders.
- The largest Cidara Therapeutics buyer in Q3 2015 was Aisling Capital, an estimated $14.6M added.
- The largest Cidara Therapeutics seller in Q3 2015 was Acuta Capital Partners, an estimated $1.01M sold.
Based on aggregated 13F filings for Q3 2015.